Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery

NCT03245346 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this randomized controlled trial is to investigate the effects of epidural anesthesia and analgesia on the overall survival,disease-free survival and recovery in patients undergoing pancreatic cancer surgery. This study will also evaluate the effects of this technique on neuroendocrine, stress and inflammatory response in these patients.

Conditions

  • Cancer of Pancreas

Interventions

DRUG

GEA

Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.

DRUG

PCEA

Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.

DRUG

GA

General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.

DRUG

PCIA

Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Changhong Miao · Fudan University

  • Qianjin Liu · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-19
Primary Completion
2023-06-30
Completion
2025-09-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245346 on ClinicalTrials.gov